华大基因(300676) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 35.86% to CNY 72,104,460.71 year-on-year[4] - Operating revenue for the period was CNY 780,923,650.57, representing a 16.01% increase compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was CNY 49,669,580.70, down 50.03% year-on-year[4] - Basic earnings per share decreased by 35.71% to CNY 0.18[4] - The weighted average return on net assets was 1.66%, a decrease of 0.97% compared to the previous year[4] - The company reported a net cash flow from operating activities of CNY -146,781,605.20, a decrease of 0.53% year-on-year[4] - The company reported a significant decrease in investment income, down 87.86% to ¥4,595,471.70, due to reduced interest income from financial products[14] - The company reported a total profit of ¥91,531,948.23, down from ¥141,660,182.08, a decrease of 35.4%[33] - The net profit for the current period was ¥71,461,870.25, down 41.2% from ¥121,511,411.15 in the previous period[33] Assets and Liabilities - Total assets increased by 7.18% to CNY 5,628,615,644.21 compared to the end of the previous year[4] - The total current assets amounted to CNY 3,257,238,813.17, slightly down from CNY 3,281,880,678.27[24] - The company reported a total non-current asset of CNY 2,371,376,831.04, an increase from CNY 1,969,519,623.18[24] - Total liabilities increased to CNY 1,074,747,874.31, up from CNY 999,039,932.39, representing a growth of approximately 7.6% year-over-year[25] - Owner's equity reached CNY 4,553,867,769.90, an increase from CNY 4,252,360,369.06, reflecting a growth of about 7.1% compared to the previous year[26] - The total current liabilities rose to CNY 976,095,875.33, compared to CNY 913,249,843.73, indicating an increase of approximately 6.9% year-over-year[25] Cash Flow - The company’s cash flow from financing activities showed a net inflow of 30,594,088.87 CNY, recovering from a net outflow of -200,050,000.00 CNY last year[48] - The net cash flow from investment activities decreased by 163.61%, resulting in a negative cash flow of ¥219,188,133.79, attributed to reduced net inflow from financial products and increased cash payments for investments[14] - The net cash flow from operating activities was -374,172,645.44 CNY, an improvement from -892,142,260.82 CNY in the previous year[47] - The cash flow from operating activities showed a net outflow of CNY 146,781,605.20, slightly worse than the previous year's outflow of CNY 146,012,213.64[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,279[7] - The largest shareholder, Shenzhen BGI Technology Co., Ltd., holds 37.18% of the shares[7] - The controlling shareholder pledged 137,284,000 shares, representing 89.90% of their holdings, which is 34.31% of the company's total equity[16] Investments and Expenditures - The company established a wholly-owned subsidiary in Qingdao with a registered capital of ¥50 million for the "Qingdao BGI Health Medical Industrial Park" project, with a planned investment of ¥470 million[18] - Development expenditures rose by 125.07% to ¥8,794,629.46 from ¥3,907,554.18, driven by ongoing investments in capitalized R&D projects[13] - Research and development expenses rose by 41.24% to ¥227,593,151.18, reflecting the company's ongoing commitment to increasing R&D investment[14] Government Support - The company received government subsidies amounting to CNY 37,436,430.54 during the reporting period[6] - Other income increased by 86.46% to ¥37,596,135.93, mainly due to an increase in government subsidies[14] Market Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[40]